# A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke

> **NCT07742098** · PHASE2 · NOT_YET_RECRUITING · sponsor: **NeuroTrauma Sciences, LLC** · enrollment: 140 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** NTS-521
- **OTHER:** Placebo Control

## Key facts

- **NCT ID:** NCT07742098
- **Lead sponsor:** NeuroTrauma Sciences, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-31
- **Primary completion:** 2028-12-15
- **Final completion:** 2028-12-15
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07742098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07742098, "A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07742098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*